[1] Ozand PT, Gascon GG, Al Essa M, et al. Biotin-responsive basal ganglia disease:a novel entity[J]. Brain, 1998, 121(Pt 7):1267-1279.
[2] Ferreira CR, Whitehead MT, Leon E. Biotin-thiamine responsive basal ganglia disease:identification of a pyruvate peak on brain spectroscopy, novel mutation in SLC19A3, and calculation of prevalence based on allele frequencies from aggregated nextgeneration sequencing data[J]. Am J Med Genet A, 2017, 173(6):1502-1513.
[3] 张培元, 刘晓军, 张玉琴. 小婴儿生物素-硫胺素反应性基底节病一例[J]. 中华儿科杂志, 2018, 56(6):462-464.
[4] Adhisivam B, Mahto D, Mahadevan S. Biotin responsive limb weakness[J]. Indian Pediatr, 2007, 44(3):228-230.
[5] Alfadhel M, Almuntashri M, Jadah RH, et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamineresponsive basal ganglia disease:a retrospective review of the clinical, radiological and molecular findings of 18 new cases[J]. Orphanet J Rare Dis, 2013, 8:83.
[6] Bindu PS, Noone ML, Nalini A, et al. Biotin-responsive basal ganglia disease:a treatable and reversible neurological disorder of childhood[J]. J Child Neurol, 2009, 24(6):750-752.
[7] Algahtani H, Ghamdi S, Shirah B, et al. Biotin-thiamineresponsive basal ganglia disease:catastrophic consequences of delay in diagnosis and treatment[J]. Neurol Res, 2017, 39(2):117-125.
[8] Aljabri MF, Kamal NM, Arif M, et al. A case report of biotinthiamine-responsive basal ganglia disease in a Saudi child:is extended genetic family study recommended?[J]. Medicine (Baltimore), 2016, 95(40):e4819.
[9] Bin Saeedan M, Dogar MA. Teaching neuroimages:MRI findings of biotin-responsive basal ganglia disease before and after treatment[J]. Neurology, 2016, 86(7):e71-e72.
[10] Bubshait DK, Rashid A, Al-Owain MA, et al. Depression in adult patients with biotin responsive basal ganglia disease[J]. Drug Discov Ther, 2016, 10(4):223-225.
[11] Debs R, Depienne C, Rastetter A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations[J]. Arch Neurol, 2010, 67(1):126-130.
[12] Distelmaier F, Huppke P, Pieperhoff P, et al. Biotin-responsive basal ganglia disease:a treatable differential diagnosis of Leigh syndrome[J]. JIMD Rep, 2014, 13:53-57.
[13] Eichler FS, Swoboda KJ, Hunt AL, et al. Case 38-2017. A 20-year-old woman with seizures and progressive dystonia[J]. N Engl J Med, 2017, 377(24):2376-2385.
[14] El-Hajj TI, Karam PE, Mikati MA. Biotin-responsive basal ganglia disease:case report and review of the literature[J]. Neuropediatrics, 2008, 39(5):268-271.
[15] Fassone E, Wedatilake Y, DeVile CJ, et al. Treatable Leigh-like encephalopathy presenting in adolescence[J]. BMJ Case Rep, 2013, 2013:200838.
[16] Flønes I, Sztromwasser P, Haugarvoll K, et al. Novel SLC19A3 promoter deletion and allelic silencing in viotin-thiamineresponsive basal ganglia encephalopathy[J]. PLoS One, 2016, 11(2):e0149055.
[17] Kassem H, Wafaie A, Alsuhibani S, et al. Biotin-responsive basal ganglia disease:neuroimaging features before and after treatment[J]. AJNR Am J Neuroradiol, 2014, 35(10):1990-1995.
[18] Schänzer A, Döring B, Ondrouschek M, et al. Stress-induced upregulation of SLC19A3 is impaired in biotin-thiamineresponsive basal ganglia disease[J]. Brain Pathol, 2014, 24(3):270-279.
[19] Serrano M, Rebollo M, Depienne C, et al. Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency[J]. Mov Disord, 2012, 27(10):1295-1298.
[20] Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited:clinical, radiologic, and genetic findings[J]. Neurology, 2013, 80(3):261-267.
[21] Alfadhel M, Al-Bluwi A. Psychological assessment of patients with biotin-thiamine-responsive basal ganglia disease[J]. Child Neurol Open, 2017, 4:2329048X17730742.
[22] Gerards M, Kamps R, van Oevelen J, et al. Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome[J]. Brain, 2013, 136(Pt 3):882-890.
[23] Gowda VK, Srinivasan VM, Bhat M, et al. Biotin thiamin responsive basal ganglia disease in siblings[J]. Indian J Pediatr, 2018, 85(2):155-157.
[24] Haack TB, Klee D, Strom TM, et al. Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease[J]. Brain, 2014, 137(Pt 9):e296.
[25] Kevelam SH, Bugiani M, Salomons GS, et al. Exome sequencing reveals mutated SLC19A3 in patients with an earlyinfantile, lethal encephalopathy[J]. Brain, 2013, 136(Pt 5):1534-1543.
[26] Kohrogi K, Imagawa E, Muto Y, et al. Biotin-responsive basal ganglia disease:a case diagnosed by whole exome sequencing[J]. J Hum Genet, 2015, 60(7):381-385.
[27] Kono S, Miyajima H, Yoshida K, et al. Mutations in a thiaminetransporter gene and Wernicke's-like encephalopathy[J]. N Engl J Med, 2009, 360(17):1792-1794.
[28] Muthusamy K, Ekbote AV, Thomas MM, et al. Biotin thiamine responsive basal ganglia disease-a potentially treatable inborn error of metabolism[J]. Neurol India, 2016, 64(6):1328-1331.
[29] Ortigoza-Escobar JD, Serrano M, Molero M, et al. Thiamine transporter-2 deficiency:outcome and treatment monitoring[J]. Orphanet J Rare Dis, 2014, 9:92.
[30] Pérez-Dueñas B, Serrano M, Rebollo M, et al. Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency[J]. Pediatrics, 2013, 131(5):e1670-e1675.
[31] Pronicka E, Piekutowska-Abramczuk D, Ciara E, et al. New perspective in diagnostics of mitochondrial disorders:two years' experience with whole-exome sequencing at a national paediatric centre[J]. J Transl Med, 2016, 14(1):174.
[32] Pronicki M, Piekutowska-Abramczuk D, Jurkiewicz E, et al. Neuropathological characteristics of the brain in two patients with SLC19A3 mutations related to the biotin-thiamineresponsive basal ganglia disease[J]. Folia Neuropathol, 2017, 55(2):146-153.
[33] Schwarting J, Lakshmanan R, Davagnanam I. Teaching neuroimages:biotin-responsive basal ganglia disease[J]. Neurology, 2016, 86(17):e184-e185.
[34] Sremba LJ, Chang RC, Elbalalesy NM, et al. Whole exome sequencing reveals compound heterozygous mutations in SLC19A3 causing biotin-thiamine responsive basal ganglia disease[J]. Mol Genet Metab Rep, 2014, 1:368-372.
[35] Tabarki B, Alfadhel M, AlShahwan S, et al. Treatment of biotinresponsive basal ganglia disease:open comparative study between the combination of biotin plus thiamine versus thiamine alone[J]. Eur J Paediatr Neurol, 2015, 19(5):547-552.
[36] Tonduti D, Invernizzi F, Panteghini C, et al. SLC19A3 related disorder:treatment implication and clinical outcome of 2 new patients[J]. Eur J Paediatr Neurol, 2018, 22(2):332-335.
[37] Whitford W, Hawkins I, Glamuzina E, et al. Compound heterozygous SLC19A3 mutations further refine the critical promoter region for biotin-thiamine-responsive basal ganglia disease[J]. Cold Spring Harb Mol Case Stud, 2017, 3(6). pii:a001909.
[38] Yamada K, Miura K, Hara K, et al. A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations[J]. BMC Med Genet, 2010, 11:171.
[39] Ygberg S, Naess K, Eriksson M, et al. Biotin and thiamine responsive basal ganglia disease-a vital differential diagnosis in infants with severe encephalopathy[J]. Eur J Paediatr Neurol, 2016, 20(3):457-461.
[40] Kamasak T, Havalı C, İnce H, et al. Are diagnostic magnetic resonance patterns life-saving in children with biotin-thiamineresponsive basal ganglia disease?[J]. Eur J Paediatr Neurol, 2018, 22(6):1139-1149.
[41] Mir A, Alhazmi R, Albaradie R. Biotin-thiamine-responsive basal ganglia disease-a treatable metabolic disorder[J]. Pediatr Neurol, 2018, 87:80-81.
[42] Zeng WQ, Al-Yamani E, Acierno JS Jr, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3[J]. Am J Hum Genet, 2005, 77(1):16-26.
[43] Ganapathy V, Smith SB, Prasad PD. SLC19:the folate/thiamine transporter family[J]. Pflugers Arch, 2004, 447(5):641-646.
[44] Brown G. Defects of thiamine transport and metabolism[J]. J Inherit Metab Dis, 2014, 37(4):577-585.
[45] Alfadhel M, Tabarki B. SLC19A3 gene defects sorting the phenotype and acronyms:review[J]. Neuropediatrics, 2018, 49(2):83-92.
[46] Rodriguez-Melendez R, Zempleni J. Regulation of gene expression by biotin (review)[J]. J Nutr Biochem, 2003, 14(12):680-690.